481 related articles for article (PubMed ID: 16499995)
41. Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population.
Pandith AA; Shah ZA; Khan NP; Rasool R; Afroze D; Yousuf A; Wani S; Siddiqi M
Cancer Genet Cytogenet; 2010 Dec; 203(2):263-8. PubMed ID: 21156242
[TBL] [Abstract][Full Text] [Related]
42. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.
Lima-Ramos V; Pacheco-Figueiredo L; Costa S; Pardal F; Silva A; Amorim J; Lopes JM; Reis RM
Cancer Genet Cytogenet; 2008 Jan; 180(1):14-9. PubMed ID: 18068527
[TBL] [Abstract][Full Text] [Related]
43. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia.
Hadhri-Guiga B; Toumi N; Khabir A; Sellami-Boudawara T; Ghorbel A; Daoud J; Frikha M; Gargouri A; Mokdad-Gargouri R
Cancer Genet Cytogenet; 2007 Oct; 178(2):89-93. PubMed ID: 17954263
[TBL] [Abstract][Full Text] [Related]
44. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
45. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
[TBL] [Abstract][Full Text] [Related]
46. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
Tan XL; Nieters A; Hoffmeister M; Beckmann L; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2007 Aug; 17(8):639-45. PubMed ID: 17622940
[TBL] [Abstract][Full Text] [Related]
47. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation.
Oyama T; Kawamoto T; Mizoue T; Sugio K; Kodama Y; Mitsudomi T; Yasumoto K
Anticancer Res; 1997; 17(1B):583-7. PubMed ID: 9066584
[TBL] [Abstract][Full Text] [Related]
48. O6-alkylguanine-DNA alkyltransferase gene polymorphisms and the risk of primary lung cancer.
Chae MH; Jang JS; Kang HG; Park JH; Park JM; Lee WK; Kam S; Lee EB; Son JW; Park JY
Mol Carcinog; 2006 Apr; 45(4):239-49. PubMed ID: 16385589
[TBL] [Abstract][Full Text] [Related]
49. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
Langerød A; Bukholm IR; Bregård A; Lønning PE; Andersen TI; Rognum TO; Meling GI; Lothe RA; Børresen-Dale AL
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1684-8. PubMed ID: 12496062
[TBL] [Abstract][Full Text] [Related]
50. Polymorphisms in TGF-beta1 gene and the risk of lung cancer.
Kang HG; Chae MH; Park JM; Kim EJ; Park JH; Kam S; Cha SI; Kim CH; Park RW; Park SH; Kim YL; Kim IS; Jung TH; Park JY
Lung Cancer; 2006 Apr; 52(1):1-7. PubMed ID: 16499994
[TBL] [Abstract][Full Text] [Related]
51. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study.
Tseng RC; Hsieh FJ; Shih CM; Hsu HS; Chen CY; Wang YC
Cancer; 2009 Jul; 115(13):2939-48. PubMed ID: 19408343
[TBL] [Abstract][Full Text] [Related]
52. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Zhai R; Liu G; Zhou W; Su L; Heist RS; Lynch TJ; Wain JC; Asomaning K; Lin X; Christiani DC
Clin Cancer Res; 2008 Jan; 14(2):612-7. PubMed ID: 18223238
[TBL] [Abstract][Full Text] [Related]
53. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
54. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk.
Damin AP; Frazzon AP; Damin DC; Roehe A; Hermes V; Zettler C; Alexandre CO
Cancer Detect Prev; 2006; 30(6):523-9. PubMed ID: 17113725
[TBL] [Abstract][Full Text] [Related]
55. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients.
Tan XL; Popanda O; Ambrosone CB; Kropp S; Helmbold I; von Fournier D; Haase W; Sautter-Bihl ML; Wenz F; Schmezer P; Chang-Claude J
Breast Cancer Res Treat; 2006 Jun; 97(3):255-62. PubMed ID: 16331344
[TBL] [Abstract][Full Text] [Related]
56. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K; Rannala B; Traisathit P; Srikummool M; Wongchai Y; Kangwanpong D
Cancer Genet Cytogenet; 2008 Aug; 185(1):20-7. PubMed ID: 18656689
[TBL] [Abstract][Full Text] [Related]
57. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population.
Sreeja L; Syamala V; Raveendran PB; Santhi S; Madhavan J; Ankathil R
Cancer Invest; 2008 Feb; 26(1):41-6. PubMed ID: 18181044
[TBL] [Abstract][Full Text] [Related]
58. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers.
Yu MW; Yang SY; Chiu YH; Chiang YC; Liaw YF; Chen CJ
Hepatology; 1999 Mar; 29(3):697-702. PubMed ID: 10051470
[TBL] [Abstract][Full Text] [Related]
59. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
[TBL] [Abstract][Full Text] [Related]
60. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.
Papadakis ED; Soulitzis N; Spandidos DA
Br J Cancer; 2002 Oct; 87(9):1013-8. PubMed ID: 12434294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
